Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11764964 | 0.95 | LMNA (0.56) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1533298 | 0.89 | NPC1 (0.72) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6814347 | 0.89 | NPC1 (0.67) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL8742927 | 0.88 | NPC1 (0.65) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL452462 | 0.85 | PLOD2 (0.56) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL26584242 | 0.84 | NPC1 (0.82) | NPC1RAB9AKMT2AMEN1HTR7 | |
| SCHEMBL2908590 | 0.83 | PLOD2 (0.55) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2305014 | 0.83 | HSD17B3 (0.60) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL8535748 | 0.83 | KMT2A (0.63) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL4686898 | 0.82 | LMNA (0.61) | LMNANPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0150036-A1 | Azolyl-aryl-alkanole-derivatives, processes for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-07-31 | — | — | EP | claimed |
| US-20240182452-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-06 | — | — | US | disclosed |
| EP-3765022-B1 | PYRIDIN-2-YL ALKYLAMINO SUBSTITUTED HYDROXAMIC ACID AND USES THEREOF | HAWAII BIOTECH INC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11897867-B2 | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-13 | — | — | US | disclosed |
| CN-115867532-A | Inhibitors of APOL1 and uses thereof | 弗特克斯药品有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| EP-3661917-B1 | 6-((3-TRIFLUOROMETHYL)PHENYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AG (DE) | 2022-05-11 | — | — | EP | disclosed |
| US-11299461-B2 | Pyridin-2-yl alkylamino substituted hydroxamic acid and uses thereof | HAWAII BIOTECH, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2021252849-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210371383-A1 | PYRIDIN-2-YL ALKYLAMINO SUBSTITUTED HYDROXAMIC ACID AND USES THEREOF | HAWAII BIOTECH, INC. | 2021-12-02 | — | — | US | disclosed |
| US-6872851-B1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20050059729-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-03-17 | — | — | US | disclosed |
| CN-1151125-C | Compounds and methods for treating cardiovascular, inflammatory and immune disorders | ǧ��ҩƷ��˾ | 2004-05-26 | — | — | CN | disclosed |
| EP-0770064-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | MILLENIUM PHARMACEUTICALS INC (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6201016-B1 | IMMUNOSUPPRESSANT AS 5-LIPOXYGENASE INHIBITOR AND/OR AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONIST | CYTOMED INCORPORATED | 2001-03-13 | — | — | US | disclosed |
| EP-0770064-A4 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED INC (US) | 1998-01-14 | — | — | EP | disclosed |
| CN-1163610-A | Compounds and methods for treating cardiovascular, inflammatory and immune disorders | CYTOMED INC (US) | 1997-10-29 | — | — | CN | disclosed |
| US-5681966-A | ENANTIOMERICALLY ENRICHED DISUBSTITUTED TETRAHYDROFURANS, TETRAHYDROTHIOPHENES ACT AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS OR 5-LIPOXYGENASE INHIBITORS | CYTOMED, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| EP-0770064-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996000212-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | LMNA 2476/4885NPC1 541/4885RAB9A 1842/4885 |
| US-20240182452-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | PDE3A, PDE3B, PDE5A | LMNA 1006/4885NPC1 3135/4885RAB9A 384/4885 |
| US-11299461-B2 | Pyridin-2-yl alkylamino substituted hydroxamic acid and uses thereof | H1-5, HCAR3, H1-3 | LMNA 147/4885NPC1 2459/4885RAB9A 4704/4885 |
| US-20050059729-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | LMNA 3112/4885NPC1 2639/4885RAB9A 394/4885 |
| US-11897867-B2 | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer | PDE3B, PDE3A, PDE5A | LMNA 3133/4885NPC1 3319/4885RAB9A 450/4885 |
| US-20210371383-A1 | PYRIDIN-2-YL ALKYLAMINO SUBSTITUTED HYDROXAMIC ACID AND USES THEREOF | H1-5, HCAR3, H1-3 | LMNA 147/4885NPC1 2459/4885RAB9A 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.